According to a new research report “Acute Kidney Injury (AKI) Therapeutics - Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, AKI therapeutics currently exhibits a proliferating pipeline of 39 therapeutic candidates.

AKI Therapeutics Pipeline Insights

AKI or acute kidney failure is a common medical condition reported among hospitalized patients, especially those with multiple comorbid conditions. AKI can occur due to various reasons including decreased renal perfusion, and obstruction of the urinary collecting system. Dehydration, abdominal pain, rise in blood pressure, mild back pain, and vomiting are some of the symptoms associated with the disease.

AKI is diagnosed through various tests which include measurement of rise in serum creatinine, urinary output and imaging techniques including renal ultrasonography. Consumption of medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs), calcineurin inhibitors, and sulfonamide antibiotics, can result in AKI. Management of AKI requires in-depth understanding of fluid and electrolyte homeostasis, as well as appropriate use of renal replacement therapy (RRT).

Insights on Pipeline Segments

According to the research findings, majority of pipeline drug candidates are being developed for intravenous route administration. The advantage with this administration includes entire administered dose reaches the systemic circulation immediately, which increases the bioavailability of drug. Administration of therapeutics for AKI through intravenous route has shown promising results in clinical studies.

Positive Clinical Trial Results are Expected to Drive the AKI Therapeutics Pipeline Advancements

The companies who are involved in developing therapeutics for AKI have shown positive clinical results in the various phases of drug development. For instance, AM-Pharma B.V. is developing a recombinant alkaline phosphatase (recAP) enzyme, which is currently in the Phase II stage of development, for the treatment of AKI. In March 2018, AM‐Pharma B.V. announced positive results from Phase II study of recAP in patients with AKI. The STOP-AKI study showed dose-dependent relative reduction in mortality of more than 40% in the treatment group compared to the placebo group.

Strategic Advancements Plays a Pivotal Role in the AKI Therapeutics Development

In November 2018, Angion Biomedica Corp. and Sinovant Sciences HK Limited entered into a collaboration and license agreement for the development of ANG-3777 for the treatment of patients with delayed graft function (DGF) following kidney transplantation and AKI following open-heart surgery requiring cardiopulmonary bypass.

Similarly, in May 2016, A1M Pharma AB collaborated with CSL Behring LLC to investigate the potential of combination therapy of Alpha 1 Microglobulin (A1M) and plasma protein in patients suffering from pre-eclampsia and AKI. The endogenous protein A1M is expected to showcase several protective mechanisms in tissues.

Sentien Biotechnologies Inc., AM-Pharma B.V., and Quark Pharmaceuticals Inc., are some other major companies involved in the development of drug candidates for the treatment of AKI.

Browse report overview with detailed TOC on "Acute Kidney Injury (AKI) Therapeutics, 2019 - Pipeline Analysis, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments" at:https://www.pharmaproff.com/report/acute-kidney-injury-therapeutic-pipeline-analysis

AKI Therapeutics Pipeline Analysis

• By Phase
• By Molecule Type
• By Route of Administration
• By Company

The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of AKI. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, upcoming conferences, and epidemiology in seven major markets (U.S., Germany, France, U.K., Italy, Spain, and Japan). In addition, the report highlights the winning strategies of companies involved in the AKI therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in the report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to AKI.